A citation-based method for searching scientific literature

Leora Horn, Jeffrey R Infante, Karen L Reckamp, George R Blumenschein, Ticiana A Leal, Saiama N Waqar, Barbara J Gitlitz, Rachel E Sanborn, Jennifer G Whisenant, Liping Du, Joel W Neal, Jon P Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J Gibbons, Allison Holzhausen, Christine M Lovly, Heather A Wakelee. Clin Cancer Res 2018
Times Cited: 93



Jessica J Lin, Viola W Zhu, Satoshi Yoda, Beow Y Yeap, Alexa B Schrock, Ibiayi Dagogo-Jack, Nicholas A Jessop, Ginger Y Jiang, Long P Le, Kyle Gowen, Philip J Stephens, Jeffrey S Ross, Siraj M Ali, Vincent A Miller, Melissa L Johnson, Christine M Lovly, Aaron N Hata, Justin F Gainor, Anthony J Iafrate, Alice T Shaw, Sai-Hong Ignatius Ou. J Clin Oncol 2018
Times Cited: 195




List of shared articles



Times cited

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier, Fabrice Barlesi. Ther Adv Respir Dis 2019
20

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
E Gobbini, R Chiari, P Pizzutillo, P Bordi, L Ghilardi, S Pilotto, G Osman, F Cappuzzo, F Cecere, F Riccardi,[...]. Clin Transl Oncol 2020
4

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.
Adela Patcas, Ana Florica Chis, Claudia Florentina Militaru, Ioana Roxana Bordea, Ruxandra Rajnoveanu, Ovidiu Florin Coza, Reem Hanna, Tamas Tiberiu, Doina Adina Todea. Bosn J Basic Med Sci 2022
1

2

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.
Kim Tam Bui, Wendy A Cooper, Steven Kao, Michael Boyer. J Clin Med 2018
22

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease.
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter. Drugs Context 2022
0

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Elisabeth Smolle, Valentin Taucher, Joerg Lindenmann, Philipp J Jost, Martin Pichler. Cancers (Basel) 2021
7

[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].
Peng Song, Li Zhang, Congcong Shang. Zhongguo Fei Ai Za Zhi 2018
3

Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Fabrizio Tabbò, Francesco Passiglia, Silvia Novello. Curr Oncol Rep 2021
7

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Leora Horn, Ziping Wang, Gang Wu, Elena Poddubskaya, Tony Mok, Martin Reck, Heather Wakelee, Alberto A Chiappori, Dae Ho Lee, Valeriy Breder,[...]. JAMA Oncol 2021
42


The allure of 'ALUR'.
M Nagasaka, V W Zhu, S-H I Ou. Ann Oncol 2018
0

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu. Front Oncol 2021
12

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.
Takafumi Fukui, Motoko Tachihara, Tatsuya Nagano, Kazuyuki Kobayashi. Cancers (Basel) 2022
6

Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
3


How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
Bing Xia, Misako Nagasaka, Viola W Zhu, Sai-Hong Ignatius Ou, Ross A Soo. Transl Lung Cancer Res 2020
6

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Leora Horn, Jennifer G Whisenant, Heather Wakelee, Karen L Reckamp, Huan Qiao, Ticiana A Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R Blumenschein,[...]. J Thorac Oncol 2019
83


[Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
A Tiotiu, Y Billon, P Vaillant, O Menard, P Hofman, C Mascaux. Rev Mal Respir 2019
2

Is tissue still the issue in detecting molecular alterations in lung cancer?
Chong-Kin Liam, Sugamya Mallawathantri, Kwun M Fong. Respirology 2020
17